Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000963623 | Breast | DCIS | response to toxic substance | 42/1390 | 262/18723 | 1.76e-06 | 6.56e-05 | 42 |
GO:009875423 | Breast | DCIS | detoxification | 29/1390 | 152/18723 | 2.15e-06 | 7.79e-05 | 29 |
GO:009886923 | Breast | DCIS | cellular oxidant detoxification | 22/1390 | 101/18723 | 3.82e-06 | 1.16e-04 | 22 |
GO:004545421 | Breast | DCIS | cell redox homeostasis | 12/1390 | 35/18723 | 4.47e-06 | 1.34e-04 | 12 |
GO:199074823 | Breast | DCIS | cellular detoxification | 23/1390 | 116/18723 | 1.22e-05 | 3.12e-04 | 23 |
GO:009723723 | Breast | DCIS | cellular response to toxic substance | 24/1390 | 124/18723 | 1.22e-05 | 3.12e-04 | 24 |
GO:007259322 | Breast | DCIS | reactive oxygen species metabolic process | 37/1390 | 239/18723 | 1.60e-05 | 3.88e-04 | 37 |
GO:003461423 | Breast | DCIS | cellular response to reactive oxygen species | 25/1390 | 155/18723 | 1.88e-04 | 3.05e-03 | 25 |
GO:004274321 | Breast | DCIS | hydrogen peroxide metabolic process | 12/1390 | 58/18723 | 9.71e-04 | 1.08e-02 | 12 |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:200011610 | Cervix | CC | regulation of cysteine-type endopeptidase activity | 61/2311 | 235/18723 | 8.69e-09 | 7.22e-07 | 61 |
GO:004328110 | Cervix | CC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 55/2311 | 209/18723 | 2.77e-08 | 1.95e-06 | 55 |
GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
GO:00513469 | Cervix | CC | negative regulation of hydrolase activity | 81/2311 | 379/18723 | 4.27e-07 | 1.67e-05 | 81 |
GO:00104669 | Cervix | CC | negative regulation of peptidase activity | 60/2311 | 262/18723 | 1.27e-06 | 4.34e-05 | 60 |
GO:00988699 | Cervix | CC | cellular oxidant detoxification | 30/2311 | 101/18723 | 2.72e-06 | 7.93e-05 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRDX5 | SNV | Missense_Mutation | | c.205N>A | p.Glu69Lys | p.E69K | P30044 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
PRDX5 | SNV | Missense_Mutation | | c.281N>T | p.Gly94Val | p.G94V | P30044 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDX5 | SNV | Missense_Mutation | novel | c.31N>T | p.Arg11Cys | p.R11C | P30044 | protein_coding | deleterious_low_confidence(0.03) | benign(0) | TCGA-D8-A27I-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimycin+cyclophosphamide | SD |
PRDX5 | SNV | Missense_Mutation | novel | c.514A>C | p.Ile172Leu | p.I172L | P30044 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3939-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PRDX5 | SNV | Missense_Mutation | | c.604C>T | p.Leu202Phe | p.L202F | P30044 | protein_coding | deleterious(0.02) | possibly_damaging(0.836) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRDX5 | SNV | Missense_Mutation | rs148589018 | c.77N>T | p.Ala26Val | p.A26V | P30044 | protein_coding | tolerated_low_confidence(0.1) | benign(0.001) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRDX5 | SNV | Missense_Mutation | | c.341N>A | p.Ala114Asp | p.A114D | P30044 | protein_coding | tolerated(0.36) | benign(0.014) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDX5 | SNV | Missense_Mutation | novel | c.196G>A | p.Glu66Lys | p.E66K | P30044 | protein_coding | tolerated(0.36) | benign(0.039) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
PRDX5 | SNV | Missense_Mutation | novel | c.112N>C | p.Trp38Arg | p.W38R | P30044 | protein_coding | tolerated(0.17) | benign(0.003) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRDX5 | SNV | Missense_Mutation | novel | c.103G>A | p.Glu35Lys | p.E35K | P30044 | protein_coding | tolerated(0.86) | benign(0.003) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |